NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S announced a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be given a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date of this dividend is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S declared that its Board of Directors has approved a share repurchase program on Friday, February 2nd 2018, which permits the company to buyback shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Friday, November, 1st. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.02. The firm earned $4.51 billion during the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

12 Wall Street analysts have issued 1-year price objectives for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $181.58 in the next twelve months. This suggests a possible upside of 201.0% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Headlines about NVO stock have trended extremely negative on Tuesday, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a daily sentiment score of -4.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Novo Nordisk A/S.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), QUALCOMM (QCOM), NVIDIA (NVDA), Starbucks (SBUX), Cisco Systems (CSCO) and Alibaba Group (BABA).

Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Everett Harris & Co. CA (0.13%), Scout Investments Inc. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%), Boston Common Asset Management LLC (0.01%), Janney Montgomery Scott LLC (0.00%) and Birch Capital Management LLC (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Norris Perne & French LLP MI, Smithbridge Asset Management Inc. DE, Brookmont Capital Management and SG Americas Securities LLC. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was acquired by a variety of institutional investors in the last quarter, including Birch Capital Management LLC, Karani Asset Management LLC, Chemung Canal Trust Co., Janney Montgomery Scott LLC, Mckinley Capital Management LLC Delaware, We Are One Seven LLC, Calamos Advisors LLC and Ingalls & Snyder LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $60.33.

Novo Nordisk A/S has a market capitalization of $142.86 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]